Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma.

摘要: The introduction of rituximab (R) has measurably improved the outcome patients with follicular lymphoma (FL) and diffuse large B-cell (DLBCL). To evaluate FL DLBCL under R plus CHOP therapy, we performed a retrospective analysis in Yokohama City University Hematology Group Japan. Five hundred twenty-six (158, ; 368, DLBCL) were scheduled to undergo primary therapy 6 cycles full-dose R-CHOP curative intent. median observation periods living 45 months 43 months, respectively. complete response, 5-year progression-free survival (PFS), overall (OS) rates 86%, 50%, 92% group, 89%, 72%, 80% Although PFS was significantly better group than OS patients. We also found that grade 3 not statistically different from those 1-2. These findings indicate all grades should be categorized simply as "FL" regard therapy. Our results demonstrate incurability (grade 1-3B), even